{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Denileukin_Diftitox",
  "nciThesaurus": {
    "casRegistry": "173146-27-5",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A cytotoxic recombinant protein consisting of interleukin-2 (IL-2) protein sequences fused to diphtheria toxin. The IL-2 protein sequence moiety of denileukin difitox directs the cytocidal action of diphtheria toxin to cells that express IL-2 receptors. After the toxin moiety is internalized into target IL-2 receptor-expressing cells, its catalytic domain catalyzes the transfer of the ADP-ribose moiety of NAD to a posttranslationally modified histidine residue of elongation factor 2 (EF-2), called diphthamine. This covalent modification inactivates EF-2 and disrupts polypeptide chain elongation, resulting in cell death.",
    "fdaUniiCode": "25E79B5CTM",
    "identifier": "C1476",
    "preferredName": "Denileukin Diftitox",
    "semanticType": "Amino Acid, Peptide, or Protein",
    "subclassOf": [
      "C575"
    ],
    "synonyms": [
      "DAB(389)-Interleukin-2",
      "DAB(389)IL-2",
      "DAB389 Interleukin-2",
      "DAB389 Interleukin-2 Immunotoxin",
      "DAB389IL-2",
      "DAB389IL2",
      "DENILEUKIN DIFTITOX",
      "Denileukin Diftitox",
      "Interleukin-2 Fusion Protein",
      "Interleukin-2 Fusion Toxin",
      "LY335348",
      "Ontak",
      "denileukin diftitox"
    ]
  }
}